CAP Profiles

Bio

Bio

Dr. Haeffele earned her medical degree from the Duke University School of Medicine in Durham, North Carolina. She subsequently completed her combined medicine and pediatric residency training at Harvard University in Boston, Massachusetts. She also earned a Master's in Public Health from the Harvard T.H. Chan School of Public Health and completed a residency in global health through her work with Partners in Health in Rwanda. She completed her fellowship in adult cardiology and adult congenital heart disease at Stanford University in Stanford, California. She served one year as a chief fellow for the general cardiology fellowship at Stanford.

Dr. Haeffele is the Affinity Chief for the General Cardiology inpatient service at Stanford Hospital. She is an Assistant Program Director for the General Cardiology fellowship. Dr. Haeffele is also appointed Clinical Assistant Professor of Medicine and Pediatrics at Stanford University School of Medicine.

Dr. Haeffele is a board certified cardiology physician. Her research interests include management of adults with congenital heart disease, single ventricle physiology, pregnancy and congenital heart disease, adolescent transition to adult care, and echocardiography.

Clinical Focus

  • Cardiovascular Disease
  • Adult Congenital Heart Disease
  • Echocardiography
  • Interventional ECHO
  • Pregnancy
  • Fontan physiology
  • Structural Heart Disease

Academic Appointments

Administrative Appointments

  • Assistant Program Director, General Cardiology Fellowship, Stanford University (2017 - Present)
  • Affinity Chief, General Cardiology Inpatient Service, Stanford Hospital (2016 - Present)

Honors & Awards

  • Graduated with Honors, Molecular and Cellular Biology, UC-Berkeley (1997)
  • Outstanding Researcher, Department of Molecular and Cellular Biology, UC-Berkeley (2001)
  • Andrew C. Puckett Humanism in Medicine, Duke University (2007)
  • Outstanding Cardiology Fellow, Stanford University (2014)
  • Housestaff Teaching Award, Stanford University (2014)
  • Excellence in Cardiology Fellowship, American College of Cardiology (2015)

Boards, Advisory Committees, Professional Organizations

  • Member, American College of Cardiology (2012 - Present)
  • Member, American Heart Association (2012 - Present)
  • Member, International Society of Adult Congenital Heart Disease (2015 - Present)
  • Member, American Society of Echocardiography (2016 - Present)

Professional Education

  • Residency:Brigham and Women's Hospital Internal Medicine Residency (2012) MA
  • Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2016)
  • Board Certification: Echocardiography, National Board of Echocardiography (2016)
  • Fellowship:Stanford University Cardiovascular Medicine FellowshipCA
  • Fellowship:Stanford University Cardiovascular Medicine Fellowship (2015) CA
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
  • Medical Education:Duke University School of Medicine (2007) NC

Contact

  • Joyce Hages
    • Tel: 650-723-1663 (office)
  • Stanford Cardiovascular Clinic 300 Pasteur Dr Stanford, CA 94305
    • Tel: (650) 723-6459
    Fax: (650) 723-8392

Research & Scholarship

Current Research and Scholarly Interests

Adult Congenital Heart Disease

Teaching

Graduate and Fellowship Programs

Publications

All Publications

  • Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease AMERICAN JOURNAL OF CARDIOLOGY Lui, G. K., Rogers, I. S., Ding, V. Y., Hedlin, H. K., MacMillen, K., Maron, D. J., Sillman, C., Romfh, A., Dade, T. C., Haeffele, C., Grady, S. R., McElhinney, D. B., Murphy, D. J., Fernandes, S. M. 2017; 119 (1): 112-118

    Abstract

    The adult with congenital heart disease (CHD) is at risk of developing atherosclerotic cardiovascular disease (ASCVD). We performed a cross-sectional study to describe established ASCVD risk factors and estimate 10-year and lifetime risk of ASCVD in adults over age 18 with CHD of moderate or great complexity using 3 validated risk assessment tools-the Framingham Study Cardiovascular Disease Risk Assessment, the Reynolds Risk Score, and the ASCVD Risk Estimator. We obtained extensive clinical and survey data on 178 enrolled patients, with average age 37.1 ± 12.6 years, 51% men. At least 1 modifiable ASCVD risk factor was present in 70%; the 2 most common were overweight/obesity (53%) and systemic hypertension (24%). Laboratory data were available in 103 of the 178 patients. Abnormal levels of glycated hemoglobin, high-sensitivity C-reactive protein, and high-density lipoprotein were each found in around 30% of patients. The 10-year ASCVD predicted risk using all 3 tools was relatively low (i.e., at least 90% of patients <10% risk), yet the median estimated lifetime risk was 36%. In conclusion, ASCVD risk factors are prevalent in adults with CHD. The risk estimation tools suggest that this population is particularly vulnerable to ASCVD with aging and should undergo guideline-based screening and management of modifiable risk factors.

    View details for DOI 10.1016/j.amjcard.2016.09.023

    View details for Web of Science ID 000391246900018

    View details for PubMedID 28247847

    View details for PubMedCentralID PMC5334785

  • Dextro-Transposition of the Great Arteries Long-term Sequelae of Atrial and Arterial Switch CARDIOLOGY CLINICS Haeffele, C., Lui, G. K. 2015; 33 (4): 543-?

    View details for DOI 10.1016/j.ccl.2015.07.012

    View details for Web of Science ID 000364729200006

    View details for PubMedID 26471819

  • Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs MOLECULAR CELL Gaillard, S., Grasfeder, L. L., Haeffele, C. L., Lobenhofer, E. K., Chu, T., Wolfinger, R., Kazmin, D., Koves, T. R., Muoio, D. M., Chang, C., McDonnell, D. P. 2006; 24 (5): 797-803

    Abstract

    In the absence of specific high-affinity agonists and antagonists, it has been difficult to define the target genes and biological responses attributable to many of the orphan nuclear receptors (ONRs). Indeed, it appears that many members of this receptor superfamily are not regulated by classical small molecules but rather their activity is controlled by interacting cofactors. Motivated by this finding, we have developed an approach to genetically isolate specific receptor-cofactor pairs in cells, allowing us to define the biological responses attributable to each complex. This is accomplished by using combinatorial peptide phage display to engineer the receptor interacting domain of each cofactor such that it interacts selectively with one nuclear receptor. In this study, we describe the customization of PGC-1alpha and its use to study the biology of the estrogen-related receptor alpha (ERRalpha) in cultured liver cells.

    View details for DOI 10.1016/j.molcel.2006.10.012

    View details for Web of Science ID 000242812000015

    View details for PubMedID 17157261